Literature DB >> 23051099

Prevalence of undiagnosed and undertreated chronic obstructive pulmonary disease in lung cancer population.

Jing Zhang1, Jie-bai Zhou, Xin-feng Lin, Qun Wang, Chun-xue Bai, Qun-ying Hong.   

Abstract

BACKGROUND AND
OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is a risk factor and important coexisting disease for lung cancer; however, the current status of management of COPD in lung cancer patients is not fully described. This study addressed this issue in a general teaching hospital in China.
METHODS: Medical records of hospitalized lung cancer patients in Zhongshan Hospital, Fudan University, between January 2006 and December 2010 were reviewed. The definition of COPD was according to the spirometric criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) document. The diagnostic rate (COPD recorded as a discharge diagnosis/spirometry-defined percentage) and conformity to GOLD treatment guidelines were investigated. The factors influencing diagnosis were analysed.
RESULTS: During the study period, the prevalence of spirometry-defined COPD in hospitalized lung cancer patients was 21.6% (705/3263). The overall diagnostic rate of COPD was 7.1%, and the treatment conformity for stable and acute exacerbation of COPD was 27.1% and 46.8%, respectively. Respiratory physicians had a higher diagnostic rate than non-respiratory doctors (34.8% vs 2.9%, P < 0.001) and a better treatment conformity for acute exacerbation of COPD (63.6% vs 37.5%, P = 0.048). Patients with COPD as a discharge diagnosis had more chance to receive guideline-consistent treatment. The diagnostic rate of COPD was higher among patients with a history of smoking, respiratory diseases or symptoms.
CONCLUSIONS: COPD is substantially underdiagnosed and undertreated in a hospitalized lung cancer population. History of smoking, respiratory diseases and symptoms promotes diagnosis. Education of COPD knowledge among patients and doctors is urgently required in this special population.
© 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Year:  2013        PMID: 23051099     DOI: 10.1111/j.1440-1843.2012.02282.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  17 in total

1.  Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.

Authors:  Laurie E Steffen McLouth; Thomas W Lycan; Beverly J Levine; Jennifer Gabbard; Jimmy Ruiz; Michael Farris; Stefan C Grant; Nicholas M Pajewski; Kathryn E Weaver; W Jeffrey Petty
Journal:  Clin Lung Cancer       Date:  2019-11-29       Impact factor: 4.785

Review 2.  Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  Chi Chiu Leung; José M Porcel; Kazuhisa Takahashi; Marcos I Restrepo; Pyng Lee; Claire Wainwright
Journal:  Respirology       Date:  2014-02-21       Impact factor: 6.424

3.  Status of coexisting chronic obstructive pulmonary disease and its clinicopathological features in patients undergoing lung cancer surgery: a cross-sectional study of 3,006 cases.

Authors:  Xiang-Lin Hu; Song-Tao Xu; Xiao-Cen Wang; Dong-Ni Hou; Cui-Cui Chen; Dong Yang; Yuan-Lin Song
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer.

Authors:  Woo Ho Ban; Jong Min Lee; Jick Hwan Ha; Chang Dong Yeo; Hyeon Hui Kang; Chin Kook Rhee; Hwa Sik Moon; Sang Haak Lee
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

5.  Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study.

Authors:  Naozumi Hashimoto; Akira Ando; Shingo Iwano; Koji Sakamoto; Shotaro Okachi; Asuka Matsuzaki; Yu Okada; Kenji Wakai; Kohei Yokoi; Yoshinori Hasegawa
Journal:  BMC Pulm Med       Date:  2018-01-05       Impact factor: 3.317

6.  Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer.

Authors:  Hai-Xing Zhu; Lin Shi; Yong Zhang; Yi-Chun Zhu; Chun-Xue Bai; Xiang-Dong Wang; Jie-Bai Zhou
Journal:  J Transl Med       Date:  2017-03-24       Impact factor: 5.531

7.  miR-98 targets ITGB3 to inhibit proliferation, migration, and invasion of non-small-cell lung cancer.

Authors:  Ran Ni; Yongjie Huang; Jing Wang
Journal:  Onco Targets Ther       Date:  2015-09-22       Impact factor: 4.147

8.  Prospectively collected characteristics of adult patients, their consultations and outcomes as they report breathlessness when presenting to general practice in Australia.

Authors:  David C Currow; Katherine Clark; Geoffrey K Mitchell; Miriam J Johnson; Amy P Abernethy
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

9.  Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients.

Authors:  Naozumi Hashimoto; Asuka Matsuzaki; Yu Okada; Naoyuki Imai; Shingo Iwano; Kenji Wakai; Kazuyoshi Imaizumi; Kohei Yokoi; Yoshinori Hasegawa
Journal:  BMC Pulm Med       Date:  2014-02-05       Impact factor: 3.317

Review 10.  Diagnosing COPD: advances in training and practice - a systematic review.

Authors:  Vladimir Koblizek; Barbora Novotna; Zuzana Zbozinkova; Karel Hejduk
Journal:  Adv Med Educ Pract       Date:  2016-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.